These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33393509)

  • 1. Immune MAL2-practice: breast cancer immunoevasion via MHC class I degradation.
    Dersh D; Yewdell JW
    J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33393509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation.
    Fang Y; Wang L; Wan C; Sun Y; Van der Jeught K; Zhou Z; Dong T; So KM; Yu T; Li Y; Eyvani H; Colter AB; Dong E; Cao S; Wang J; Schneider BP; Sandusky GE; Liu Y; Zhang C; Lu X; Zhang X
    J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 32990678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion.
    Dersh D; Hollý J; Yewdell JW
    Nat Rev Immunol; 2021 Feb; 21(2):116-128. PubMed ID: 32820267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
    Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
    Front Immunol; 2019; 10():1505. PubMed ID: 31333652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MHC class I TCR engineered anti-tumor CD4 T cells: implications for cancer immunotherapy.
    Chhabra A
    Endocr Metab Immune Disord Drug Targets; 2009 Dec; 9(4):344-52. PubMed ID: 19807670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class I
    Marijt KA; Doorduijn EM; van Hall T
    Mol Immunol; 2019 Sep; 113():43-49. PubMed ID: 29627136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [MHC tetramers: tracking specific immunity].
    Kosor E; Gagro A; Drazenović V; Kuzman I; Jeren T; Rakusić S; Rabatić S; Markotić A; Gotovac K; Sabioncello A; Cecuk E; Kerhin-Brkljacić V; Gjenero-Margan I; Kaić B; Mlinarić-Galinović G; Kastelan A; Dekaris D
    Acta Med Croatica; 2003; 57(4):255-9. PubMed ID: 14639858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteolysis-Targeting Chimeras Enhance T Cell Bispecific Antibody-Driven T Cell Activation and Effector Function through Increased MHC Class I Antigen Presentation in Cancer Cells.
    Massafra V; Tundo S; Dietzig A; Ducret A; Jost C; Klein C; Kontermann RE; Knoetgen H; Steegmaier M; Romagnani A; Nagel YA
    J Immunol; 2021 Jul; 207(2):493-504. PubMed ID: 34215653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor CEMIP drives immune evasion of colorectal cancer via MHC-I internalization and degradation.
    Zhang B; Li J; Hua Q; Wang H; Xu G; Chen J; Zhu Y; Li R; Liang Q; Wang L; Jin M; Tang J; Lin Z; Zhao L; Zhang D; Yu D; Ren J; Zhang T
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36596591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy-Induced MHC I Ligands Shape Neo-Antitumor CD8 T Cell Responses during Oncolytic Virus-Based Cancer Immunotherapy.
    Murphy JP; Kim Y; Clements DR; Konda P; Schuster H; Kowalewski DJ; Paulo JA; Cohen AM; Stevanovic S; Gygi SP; Gujar S
    J Proteome Res; 2019 Jun; 18(6):2666-2675. PubMed ID: 31095916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of exosomal MHC-I promotes glioma cells escaping from systemic immunosurveillance.
    Sun T; Li Y; Wu J; Cao Y; Yang Y; He Y; Huang W; Liu B; Yang W
    Nanomedicine; 2022 Nov; 46():102605. PubMed ID: 36113830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It.
    Shklovskaya E; Rizos H
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting MHC-I inhibitory pathways for cancer immunotherapy.
    Wang J; Lu Q; Chen X; Aifantis I
    Trends Immunol; 2024 Mar; 45(3):177-187. PubMed ID: 38433029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy.
    Bao Y; Qiao Y; Choi JE; Zhang Y; Mannan R; Cheng C; He T; Zheng Y; Yu J; Gondal M; Cruz G; Grove S; Cao X; Su F; Wang R; Chang Y; Kryczek I; Cieslik M; Green MD; Zou W; Chinnaiyan AM
    Proc Natl Acad Sci U S A; 2023 Dec; 120(49):e2314416120. PubMed ID: 38011559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Learning from the Proteasome How To Fine-Tune Cancer Immunotherapy.
    Vigneron N; Abi Habib J; Van den Eynde BJ
    Trends Cancer; 2017 Oct; 3(10):726-741. PubMed ID: 28958390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells.
    Morrison BJ; Steel JC; Morris JC
    BMC Cancer; 2018 Apr; 18(1):469. PubMed ID: 29699516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MHC class I presented antigens from malignancies: A perspective on analytical characterization & immunogenicity.
    Schmidt M; Lill JR
    J Proteomics; 2019 Jan; 191():48-57. PubMed ID: 29698800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.
    Kissick HT; Sanda MG; Dunn LK; Arredouani MS
    PLoS One; 2014; 9(4):e93231. PubMed ID: 24690990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.